Rosch F

References (11)

Title : In vitro kinetic profiling by enzymatic approaches to select FAPIs with a long residence time - Verhulst_2026_Eur.J.Med.Chem_304_118494
Author(s) : Verhulst E , Brzeminski P , de Groot A , Wals JW , Michiels R , Fabisiak A , Thys J , Grintsevich S , Van Rymenant Y , Peeters S , Lambregts S , Sim Y , Verstraete R , Van Wielendaele P , Berg M , Elvas F , Van Ostade X , Rosch F , Lambeir AM , De Winter H , Van der Veken P , De Meester I
Ref : Eur Journal of Medicinal Chemistry , 304 :118494 , 2026
Abstract :
PubMedSearch : Verhulst_2026_Eur.J.Med.Chem_304_118494
PubMedID: 41455278
Gene_locus related to this paper: human-FAP

Title : Preclinical evaluation of DOTAGA.Glu.(FAPI)(2) and DO3A.Glu.(FAPI)(2) as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs - Bilinska_2026_Eur.J.Nucl.Med.Mol.Imaging_53_1887
Author(s) : Bilinska A , Kumar N , Gnesin S , Lappchen T , Menendez E , Martin M , Rosch F , Rominger A , Gourni E
Ref : Eur J Nucl Med Mol Imaging , 53 :1887 , 2026
Abstract :
PubMedSearch : Bilinska_2026_Eur.J.Nucl.Med.Mol.Imaging_53_1887
PubMedID: 41105225

Title : Structure-Property Investigation of New KetoFAPI Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential - Brzeminski_2025_J.Med.Chem_68_21739
Author(s) : Brzeminski P , Verhulst E , Fabisiak A , Pacifico R , Willocx D , Peeters S , de Groot A , Corthaut S , Van Meel K , Stroobants S , Augustyns K , Berg M , Lambeir AM , Rosch F , De Meester I , Elvas F , Van der Veken P
Ref : Journal of Medicinal Chemistry , 68 :21739 , 2025
Abstract :
PubMedSearch : Brzeminski_2025_J.Med.Chem_68_21739
PubMedID: 41086263
Gene_locus related to this paper: human-FAP

Title : Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the (68)Ga- and (177)Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)(2) - Lappchen_2024_Molecules_29_
Author(s) : Lappchen T , Bilinska A , Pilatis E , Menendez E , Imlimthan S , Moon ES , Afshar-Oromieh A , Rosch F , Rominger A , Gourni E
Ref : Molecules , 29 : , 2024
Abstract :
PubMedSearch : Lappchen_2024_Molecules_29_
PubMedID: 38999044

Title : Next generation fibroblast activation protein (FAP) targeting PET tracers - The tetrazine ligation allows an easy and convenient way to (18)F-labeled (4-quinolinoyl)glycyl-2-cyanopyrrolidines - Poulie_2023_Eur.J.Med.Chem_262_115862
Author(s) : Poulie CBM , Shalgunov V , Elvas F , Van Rymenant Y , Moon ES , Battisti UM , De Loose J , De Meester I , Rosch F , Van der Veken P , Herth MM
Ref : Eur Journal of Medicinal Chemistry , 262 :115862 , 2023
Abstract :
PubMedSearch : Poulie_2023_Eur.J.Med.Chem_262_115862
PubMedID: 37883899

Title : Translational assessment of a DATA-functionalized FAP inhibitor with facile (68)Ga-labeling at room temperature - Escudero-Castellanos_2023_Eur.J.Nucl.Med.Mol.Imaging_50_3202
Author(s) : Escudero-Castellanos A , Kurth J , Imlimthan S , Menendez E , Pilatis E , Moon ES , Lappchen T , Rathke H , Schwarzenbock SM , Krause BJ , Rosch F , Rominger A , Gourni E
Ref : Eur J Nucl Med Mol Imaging , 50 :3202 , 2023
Abstract :
PubMedSearch : Escudero-Castellanos_2023_Eur.J.Nucl.Med.Mol.Imaging_50_3202
PubMedID: 37284857

Title : New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress - Imlimthan_2021_Pharmaceuticals.(Basel)_14_
Author(s) : Imlimthan S , Moon ES , Rathke H , Afshar-Oromieh A , Rosch F , Rominger A , Gourni E
Ref : Pharmaceuticals (Basel) , 14 : , 2021
Abstract :
PubMedSearch : Imlimthan_2021_Pharmaceuticals.(Basel)_14_
PubMedID: 34681246
Gene_locus related to this paper: human-FAP

Title : In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA(5).SA.FAPi and DOTA.SA.FAPi - Moon_2021_Molecules_26_3482
Author(s) : Moon ES , Van Rymenant Y , Battan S , De Loose J , Bracke A , Van der Veken P , De Meester I , Rosch F
Ref : Molecules , 26 :3482 , 2021
Abstract :
PubMedSearch : Moon_2021_Molecules_26_3482
PubMedID: 34201111
Gene_locus related to this paper: human-FAP

Title : Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators - Moon_2020_EJNMMI.Radiopharm.Chem_5_19
Author(s) : Moon ES , Elvas F , Vliegen G , De Lombaerde S , Vangestel C , De Bruycker S , Bracke A , Eppard E , Greifenstein L , Klasen B , Kramer V , Staelens S , De Meester I , Van der Veken P , Rosch F
Ref : EJNMMI Radiopharm Chem , 5 :19 , 2020
Abstract :
PubMedSearch : Moon_2020_EJNMMI.Radiopharm.Chem_5_19
PubMedID: 32728930

Title : Demonstration of pulmonary beta2-adrenergic receptor binding in vivo with [18F]fluoroethyl-fenoterol in a guinea pig model - Helisch_2005_Eur.J.Nucl.Med.Mol.Imaging_32_1324
Author(s) : Helisch A , Schirrmacher E , Thews O , Schirrmacher R , Buchholz HG , Dillenburg W , Hohnemann S , Tillmanns J , Wessler I , Buhl R , Rosch F , Bartenstein P
Ref : Eur J Nucl Med Mol Imaging , 32 :1324 , 2005
Abstract :
PubMedSearch : Helisch_2005_Eur.J.Nucl.Med.Mol.Imaging_32_1324
PubMedID: 16133376

Title : Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[(18)F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-ben zene-1,3-diol ([(18)F]FEFE) for the in vivo visualisation and quantification of the beta2-adrenergic receptor status in lung - Schirrmacher_2003_Bioorg.Med.Chem.Lett_13_2687
Author(s) : Schirrmacher E , Schirrmacher R , Thews O , Dillenburg W , Helisch A , Wessler I , Buhl R , Hohnemann S , Buchholz HG , Bartenstein P , Machulla HJ , Rosch F
Ref : Bioorganic & Medicinal Chemistry Lett , 13 :2687 , 2003
Abstract :
PubMedSearch : Schirrmacher_2003_Bioorg.Med.Chem.Lett_13_2687
PubMedID: 12873495